Evaluation of ciprofloxacin-loaded Eudragit® RS100 or RL100/PLGA nanoparticles

被引:192
作者
Dillen, Kathleen
Vandervoort, Jo
Van den Mooter, Guy
Ludwig, Annick
机构
[1] Univ Antwerp, Lab Pharmaceut Technol & Biopharm, Dept Pharmaceut Sci, B-2610 Antwerp, Belgium
[2] Katholieke Univ Leuven, Lab Pharm Technol & Biopharm, O&N, B-3000 Louvain, Belgium
关键词
Eudragit((R)) RS100; Eudragit (R) RL100; PLGA nanoparticles; ciprofloxacin;
D O I
10.1016/j.ijpharm.2006.01.041
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The objective of present study was to prepare positively charged ciprofloxacin-loaded nanoparticles providing a controlled release formulation. The particles were prepared by water-in-oil-in-water (w/o/w) emulsification and solvent evaporation, followed by high-pressure homogenisation. Two non-biodegradable positively charged polymers, Eudragit (R) RS100 and RL100, and the biodegradable polymer poly(lactic-co-glycolic acid) or PLGA were used alone or in combination, with varying ratios. The formulations were evaluated in terms of particle size and zeta potential. Differential scanning calorimetry measurements were carried out on the nanoparticles and on the pure polymers Eudragit and PLGA. Drug loading and release properties of the nanoparticles were examined. The antimicrobial activity against Pseudomonas aeruginosa and Staphylococcus aureus was determined. During solvent evaporation, the size and zeta potential of the nanoparticles did not change significantly. The mean diameter was dependent on the presence of Eudragit (R) and on the viscosity of the organic phase. The zeta potential of all Eudragit (R) containing nanoparticles was positive in ultrapure water (around +21/+25 mV). No burst effect but a prolonged drug release was observed from all formulations. The particles' activity against R aeruginosa and S. aureus was comparable with an equally concentrated ciprofloxacin solution. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:72 / 82
页数:11
相关论文
共 40 条
[1]
The microbiology of the eye [J].
Armstrong, RA .
OPHTHALMIC AND PHYSIOLOGICAL OPTICS, 2000, 20 (06) :429-441
[2]
PLGA nanoparticles in drug delivery: The state of the art [J].
Bala, I ;
Hariharan, S ;
Kumar, MNVR .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2004, 21 (05) :387-422
[3]
PAMPA -: a drug absorption in vitro model 7.: Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones [J].
Bermejo, M ;
Avdeef, A ;
Ruiz, A ;
Nalda, R ;
Ruell, JA ;
Tsinman, O ;
González, I ;
Fernández, C ;
Sánchez, G ;
Garrigues, TM ;
Merino, V .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 21 (04) :429-441
[4]
Fluoroquinolones: Mechanism of action, classification, and development of resistance [J].
Blondeau, JM .
SURVEY OF OPHTHALMOLOGY, 2004, 49 :S73-S78
[5]
Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases [J].
Bourcier, T ;
Thomas, F ;
Borderie, V ;
Chaumeil, C ;
Laroche, L .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2003, 87 (07) :834-838
[6]
Bozkir Asuman, 2005, Farmaco (Lausanne), V60, P840, DOI 10.1016/j.farmac.2005.06.016
[7]
The design of nanoparticles obtained by solvent evaporation: A comprehensive study [J].
Desgouilles, S ;
Vauthier, C ;
Bazile, D ;
Vacus, J ;
Grossiord, JL ;
Veillard, M ;
Couvreur, P .
LANGMUIR, 2003, 19 (22) :9504-9510
[8]
Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles [J].
Dillen, K ;
Vandervoort, J ;
Van den Mooter, G ;
Verheyden, L ;
Ludwig, A .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 275 (1-2) :171-187
[9]
Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles [J].
Dunne, M ;
Corrigan, OI ;
Ramtoola, Z .
BIOMATERIALS, 2000, 21 (16) :1659-1668
[10]
In vitro susceptibilities to topical antibiotics of bacteria isolated from the surface of clinically symptomatic eyes [J].
Egger, SF ;
Ruckhofer, J ;
Alzner, E ;
Hell, M ;
Hitzl, W ;
Huber-Spitzy, V ;
Grabner, G .
OPHTHALMIC RESEARCH, 2001, 33 (02) :117-120